A comparison of the inhibitory effects of four volatile anaesthetics on the metabolism of chlorzoxazone, a substrate for CYP2E1, in rabbits

被引:6
|
作者
Tateishi, T
Watanabe, M
Nakura, H
Tanaka, M
Kumai, T
Aoki, T
Kobayashi, S
机构
[1] St Marianna Univ, Sch Med, Dept Pharmacol, Kanagawa, Japan
[2] St Marianna Univ, Sch Med, Dept Anesthesiol, Kanagawa, Japan
关键词
halothane; isoflurane; enflurane; sevoflurane; chlorzoxazone; drug-interaction; rabbits;
D O I
10.1111/j.1399-6576.1998.tb05371.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Halothane inhibits in vitro and in vivo activity of cytochrome P-450 (CYP) 2E1. There are several fluorinated volatile anaesthetics besides halothane, and most of them are defluorinated by CYP2E1. It is unclear whether other fluorinated anaesthetics inhibit the in vivo activity of CYP2E1. Methods: We compared the inhibitory effects of therapeutic concentrations of four inhalational anaesthetics, halothane, enflurane, isoflurane, and sevoflurane, on chlorzoxazone metabolism in rabbits receiving artificial ventilation. Results: All four inhalational anaesthetics decreased arterial blood pressure and increased plasma chlorzoxazone concentration. However, no significant differences in the plasma chlorzoxazone concentration were found between the four anaesthetics. The estimated chlorzoxazone clearance increased after beginning inhalation with all four agents, but no significant difference in clearance was noted between agents. Conclusions: At therapeutic concentrations, the in vivo inhibitory effect on chlorzoxazone metabolism was similar for all four inhalational anaesthetics examined, even though their chemical characteristics and extent of hepatic metabolism differ considerably.
引用
收藏
页码:1028 / 1032
页数:5
相关论文
共 50 条
  • [31] The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain
    Garcia-Suastegui, W. A.
    Ramos-Chavez, L. A.
    Rubio-Osornio, M.
    Calvillo-Velasco, M.
    Atzin-Mendez, J. A.
    Guevara, J.
    Silva-Adaya, D.
    OXIDATIVE MEDICINE AND CELLULAR LONGEVITY, 2017, 2017
  • [32] ACETAMINOPHEN METABOLISM IN PATIENTS WITH DIFFERENT CYP2E1 GENOTYPES
    TSUTSUMI, M
    UESHIMA, Y
    TAKASE, S
    MATSUDA, Y
    KAWAHARA, H
    HEPATOLOGY, 1995, 22 (04) : 1585 - 1585
  • [33] Mutagenesis and computational docking simulations of CYP2E1 metabolism
    Levy, Joseph W.
    Miller, Grover P.
    Perry, Martin D.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [34] ACETAMINOPHEN METABOLISM IN SUBJECTS WITH DIFFERENT CYP2E1 GENOTYPES
    TSUTSUMI, M
    WANG, JS
    UESHIMA, Y
    TAKASE, S
    TAKADA, A
    HEPATOLOGY, 1994, 20 (04) : A409 - A409
  • [35] CYP2E1 in 1,4-dioxane metabolism and liver toxicity: insights from CYP2E1 knockout mice study
    Wang, Yewei
    Charkoftaki, Georgia
    Orlicky, David J.
    Davidson, Emily
    Aalizadeh, Reza
    Sun, Ning
    Ginsberg, Gary
    Thompson, David C.
    Vasiliou, Vasilis
    Chen, Ying
    ARCHIVES OF TOXICOLOGY, 2024, 98 (10) : 3241 - 3257
  • [36] Watercress inhibits human CYP2E1 activin in vivo as measured by chlorzoxazone 6-hydroxylation.
    Kim, RB
    Wilkinson, GR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 59 (02) : PII46 - PII46
  • [37] In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African green monkeys: Induction by chronic nicotine treatment
    Lee, Anna M.
    Yue, Jiang
    Tyndale, Rachel F.
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (09) : 1508 - 1515
  • [38] Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation
    Burckart, GJ
    Frye, RF
    Kelly, P
    Branch, RA
    Jain, A
    Fung, JJ
    Starzl, TE
    Venkataramanan, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (03) : 296 - 302
  • [39] Genetic and dietary predictors of CYP2E1 activity: A phenotyping study in Hawaii Japanese using chlorzoxazone
    Le Marchand, L
    Wilkinson, GR
    Wilkens, LR
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 1999, 8 (06) : 495 - 500
  • [40] An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A)
    Palmer, JL
    Scott, RJ
    Gibson, A
    Dickins, M
    Pleasance, S
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (05) : 555 - 561